肝细胞β-catenin缺陷加重致癌性β-catenin与MET驱动的肝癌发生
在致癌性β-catenin(CAT)联合MET驱动的小鼠肝癌模型中,肝细胞敲除内源性β-catenin后转录组改变、DNA损伤反应增强、Sox9+细胞扩增、促瘤细胞因子(IL-6、TGF-β1)上调,最终加重CAT/MET驱动的肝癌发生,所得肿瘤转录组与人同时携带CTNNB1突变和MET过表达的肝癌样本相似。
要点
- 肝细胞β-catenin缺陷可加重CAT/MET驱动的肝细胞癌发生。
- β-catenin缺陷肝脏中DNA损伤反应增强、Sox9+细胞扩增、IL-6与TGF-β1上调。
- 所得小鼠肿瘤转录组与人CTNNB1突变伴MET过表达的肝癌样本相似。
核心结论
- 致癌性β-catenin突变体虽具致癌性,但抑制致癌信号通路可产生促癌微环境,可能促进原发肿瘤靶向治疗后的肝癌复发。
- 有效治疗策略需同时破坏肿瘤细胞的致癌信号并抑制肝微环境中的继发性促瘤基质效应。
研究设计与样本
- 研究为小鼠实验,在肝细胞中敲除内源性β-catenin,同时转染致癌性β-catenin(CAT)与MET。
主要发现
- CAT/MET转染后促分裂信号与细胞周期进展仅轻度受损。
- β-catenin缺陷肝脏显示转录组改变、DNA损伤反应增加、Sox9+细胞扩增及促瘤细胞因子(包括白细胞介素-6和转化生长因子β1)上调。
- 上述事件最终加重CAT/MET驱动的肝癌发生,伴细胞外信号调节激酶(Erk)、蛋白激酶B(Akt)、Wnt/β-catenin信号及细胞周期蛋白D1表达上调。
- 所得小鼠肿瘤转录组与人同时携带CTNNB1突变和MET过表达的肝细胞癌样本相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Both activating and inactivating mutations in catenin β1 (ctnnb1), which encodes β-catenin, have been implicated in liver tumorigenesis in humans and mice, although the underlying mechanisms are not fully understood. Herein, we show that deletion of endogenous β-catenin in hepatocytes aggravated hepatocellular carcinoma (HCC) development driven by an oncogenic version of β-catenin (CAT) in combination with the hepatocyte growth factor receptor MET proto-oncogene receptor tyrosine kinase (MET). Although the mitogenic signaling and cell cycle progression was modestly impaired after CAT/MET transfection, the β-catenin-deficient livers displayed changes in transcriptomes, increased DNA damage response, expanded Sox9+ cells, and up-regulation of protumorigenic cytokines, including interleukin-6 and transforming growth factor β1. These events eventually exacerbated CAT/MET-driven hepatocarcinogenesis in β-catenin-deficient livers, featured by up-regulation of extracellular signal-regulated kinase (Erk), protein kinase B (Akt), and Wnt/β-catenin signaling and cyclin D1 expression. The resultant mouse tumors showed similar transcriptomes to human HCC samples with concomitant CTNNB1 mutations and MET overexpression. CONCLUSION: These data argue that while dominantly activating mutants of β-catenin are oncogenic, inhibiting the oncogenic signaling pathway generates a pro-oncogenic microenvironment that may facilitate HCC recurrence following a targeted therapy of the primary tumor. An effective therapeutic strategy must require disruption of the oncogenic signaling in tumor cells and suppression of the secondary tumor-promoting stromal effects in the liver microenvironment. (Hepatology 2018;67:1807-1822).
引用
- Liang Y, Feng Y, Zong M, et al. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET. Hepatology. 2018. PMID: 29152756. doi:10.1002/hep.29661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。